Cargando…

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy

BACKGROUND: Amyloidosis is a disease caused by deposits of insoluble fibrils in extracellular spaces. The most common type of familial amyloidosis is mediated by mutation of transthyretin, especially Val30Met. Symptoms and ejection fraction decrease may occur in cardiac amyloidosis only in case of p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Alexandre Marins, Ferreira, Suzane Garcia, Nacif, Marcelo Souto, Ribeiro, Mario Luiz, de Freitas, Marcos Raimundo Gomes, Mesquita, Cláudio Tinoco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Cardiologia - SBC 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5245844/ https://www.ncbi.nlm.nih.gov/pubmed/27992035 http://dx.doi.org/10.5935/abc.20160191

Ejemplares similares

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Cardiac Mechanics Evaluated by Speckle Tracking Echocardiography
por: Abduch, Maria Cristina Donadio, et al.
Publicado: (2014)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy
por: Knoll, Katharina, et al.
Publicado: (2023)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges
por: Bruno, Marianna, et al.
Publicado: (2020)

A Systematic Review of Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Singh, Bishnu Mohan, et al.
Publicado: (2021)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges
por: Tschöpe, Carsten, et al.
Publicado: (2022)

Clinical characteristics and prognosis of Chinese patients with hereditary transthyretin amyloid cardiomyopathy
por: He, Shan, et al.
Publicado: (2019)

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy
por: Feng, Kent Y., et al.
Publicado: (2019)

Clinical recommendations to diagnose and monitor patients with transthyretin amyloid cardiomyopathy in Asia
por: Lin, Weiqin, et al.
Publicado: (2022)

Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
por: Lauppe, Rosa, et al.
Publicado: (2022)

Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)

Health‐related quality of life among transthyretin amyloid cardiomyopathy patients
por: Eldhagen, Per, et al.
Publicado: (2023)

Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy
por: Rettl, René, et al.
Publicado: (2023)

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
por: Tomasoni, Daniela, et al.
Publicado: (2023)

Speckle tracking echocardiography in cats with preclinical hypertrophic cardiomyopathy
por: Spalla, Ilaria, et al.
Publicado: (2019)

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy
por: Morioka, Mami, et al.
Publicado: (2022)

Practical Implications of Myocardial Viability Studies
por: Ker, Wilter dos Santos, et al.
Publicado: (2018)

Speckle tracking echocardiography in hypokinetic non‐dilated cardiomyopathy: comparison with dilated cardiomyopathy
por: Mombeini, Hoda, et al.
Publicado: (2020)

Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis
por: Benson, Merrill D, et al.
Publicado: (2015)

Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan
por: Yamada, Toshihiro, et al.
Publicado: (2020)

Estimating the Prevalence of Transthyretin Amyloid Cardiomyopathy in a Large In-Hospital Database in Japan
por: Winburn, Ian, et al.
Publicado: (2019)

Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Dorbala, Sharmila, et al.
Publicado: (2021)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
por: Nativi‐Nicolau, Jose, et al.
Publicado: (2021)

False‐positive bone scintigraphy denoting transthyretin amyloid in elderly hypertrophic cardiomyopathy
por: Chimenti, Cristina, et al.
Publicado: (2021)

Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis
por: Patel, Rishi K., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v0ajd8li1le6gv2ji0h5b28dg8